UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 7, 2024

 

Dermata Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-40739

 

86-3218736

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

3525 Del Mar Heights Rd., #322 San Diego, CA

 

92130

(Address of principal executive offices)

 

(Zip Code)

 

(858) 800-2543

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class:

 

Trading Symbol

 

Name of Each Exchange on which Registered

Common Stock, par value $0.0001 per share

 

DRMA

 

The Nasdaq Capital Market

Warrants, exercisable for one share of Common Stock

 

DRMAW

 

The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On August 7, 2024, Dermata Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the quarter ended June 30, 2024. A copy of the press release is furnished under Item 2.02 as Exhibit 99.1.

 

The information included in this Item 2.02 and Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed “filed” for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934 as amended (the “Exchange Act”). Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act made after the date hereof, the information contained in this Item 2.02 and Exhibit 99.1 hereto shall not be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

Item 7.01. Regulation FD Disclosure.

 

See “Item 2.02 Results of Operations and Financial Condition” above.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.

 

Description

99.1

 

Press Release, dated August 7, 2024, issued by Dermata Therapeutics, Inc. entitled “Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results.”

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

2

 

 

Signature

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

DERMATA THERAPEUTICS, INC.

 

 

 

 

 

Dated: August 7, 2024

By:

/s/ Gerald T. Proehl

 

 

 

Gerald T. Proehl

 

 

 

Chief Executive Officer

 

 

 

3

 

 

nullv3.24.2.u1
Cover
Aug. 07, 2024
Document Information Line Items  
Entity Registrant Name Dermata Therapeutics, Inc.
Entity Central Index Key 0001853816
Document Type 8-K
Amendment Flag false
Entity Emerging Growth Company true
Document Period End Date Aug. 07, 2024
Entity Ex Transition Period true
Entity File Number 001-40739
Entity Incorporation State Country Code DE
Entity Tax Identification Number 86-3218736
Entity Address Address Line 1 3525 Del Mar Heights Rd.
Entity Address Address Line 2 #322
Entity Address City Or Town San Diego
Entity Address State Or Province CA
Entity Address Postal Zip Code 92130
City Area Code 858
Local Phone Number 800-2543
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Common Stock, par value  
Document Information Line Items  
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol DRMA
Security Exchange Name NASDAQ
Warrants, exercisable  
Document Information Line Items  
Security 12b Title Warrants, exercisable for one share of Common Stock
Trading Symbol DRMAW
Security Exchange Name NASDAQ
Dermata Therapeutics (NASDAQ:DRMA)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024 Click aqui para mais gráficos Dermata Therapeutics.
Dermata Therapeutics (NASDAQ:DRMA)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024 Click aqui para mais gráficos Dermata Therapeutics.